Article Details
Retrieved on: 2024-09-18 20:22:14
Tags for this article:
Click the tags to see associated articles and topics
Summary
BioAge Labs, a biotech firm focusing on metabolic aging therapies, plans an IPO with significant investment from Sofinnova. Their key drug, azelaprag, is in Phase 2 trials, highlighting clinical research and the design of experiments.
Article found on: www.renaissancecapital.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here